research

Leslie Miller, M.D.

Research and Publications

Research Clinical Trials:   

 NIH funded research trials:

1988-1989           Co-Investigator: “Thrombolysis in Myocardial Infarction (TIMI): Phase II. Funded by the National Institute of Health.

1991-1993           Co-Investigator: “Pathobiology of Human Heart Allograft Arteriopathy” a study in conjunction with the University of Nebraska. Funded by the National Institute of Health. #RFA88-HL-18-H

1994-1998           Co-Investigator: “Novacor N100 Left Ventricular Assist System with Portable Controllers,” funded by the National Institute of Health.

1998-2001           Principal Investigator: “REMATCH Trial (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure),” funded by National Institute of Health.

2000 – 2004         Principal Investigator: “Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial” N01-HV-98177, funded by the National Institute of Health.

2002 -2005          Principal Investigator: “Multidisciplinary Study of Right Ventricular Dysplasia,” funded by the National Institute of Health.

2002 -2005          Co-Investigator: “ACTION: A CHF Trial Investigating Outcomes of Exercise Training,” funded by the National Institute of Health.

2002 -2004          Principal Investigator: “Multidisciplinary Study of Right Ventricular Dysplasia,” funded by the National Institute of Health.

2004 -2007          Principal Investigator: “IMAC II: Genetic Modulation of LV Recovery,” funded by the National Institute of Health.

  • Site PI: SCCOR grant. Use of Mesenchymal Stem Cells for Cardiac Recovery in Patients on LVAD as Bridge to Transplant.   Funded by National Institutes of Health

Research Clinical Trials:

1984-1985           Co-Investigator: “Development of a Method of Prolonged Myocardial Protection During Cold Storage for Transplantation” American Heart Association-funded study.

1984-1985           Co-Investigator: “Prolonged Cardiac Preservation with Control of Oxidation-Reduction Potential” an American Heart Association-funded study.

1984-1985           Co-Investigator: “Improved Myocardial Preservation with Control of Oxidation-Reduction Potential” an American Heart Association-funded study.

1986-1988           Principal Investigator: “Compassionate Clearance of Orthoclone OKT3 Treatment of Acute Rejection in Non-renal, Non-hepatic Organ transplants Where All Conventional Therapies Have Failed or are Medically Contraindicated,” sponsored by Ortho Pharmaceuticals.

1986-1988           Principal Investigator: “A Phase III Randomized Double Blind Placebo-Controlled Multicenter Study Assessing the Safety and Efficacy of Dopexamine Hydrochloride in the Treatment of Patients with Congestive Heart Failure,” sponsored by Fisons, Inc.

1986-1992           Principal Investigator: “The Use of Minnesota Anti-Lymphocyte Globulin in the Treatment of Refractory Rejection in Heart and Heart/Lung Transplant Recipients.” Am Soc Tx Phys.

1987-1988           Co-Investigator: “IL-2 Receptor Positive Cells in Cardiac Rejection” funded by the American Heart Association, Missouri Affiliate.

1987-1989           Principal Investigator: “The Use of Intravenous Dobutamine for the Treatment of Refractory Heart Failure by Means of a Permanent Venous Access and External Infusion Pump,” sponsored by the Eli Lilly Company.

1987-1989           Co-Investigator: “A Double-Blind Efficacy Comparison of Esmolol and Placebo as Add-on Therapy in Patients in the Management of Unstable Angina,” sponsored by DuPont Critical Care Pharmaceuticals.

1987-1989           Co-Investigator: “Efficacy of Esmolol on Left Ventricular Systolic and Diastolic Function in Patients with Unstable Angina” sponsored by DuPont Critical Care Pharmaceutical

1988-1989           Co-Investigator: “Thrombolysis in Myocardial Infarction (TIMI): Phase II. Funded by the National Institute of Health.

1988-1990           Co-Investigator: “MIL-1034 A Long-Term, Randomized, Phase III Survival Study of Oral Milrinone, Captopril, and Digoxin in Congestive Heart Failure Patients,” sponsored by Sterling Winhrop, Inc.

1988-1990           Co-Investigator: “A Pilot Trial of Late Thrombolysis and Delayed Revascularization in Myocardial Infarction,” sponsored by Genentech, Inc. #87-074.

1988-1990           Principal Investigator: “Hydrochloride vs. Lactobionate of    Dobutamine in the Treatment of Congestive Heart Failure,” sponsored by Eli Lilly and Company.

1989-1990           Principal Investigator: “LY206243 (S-Dobutamine) vs. Dopamine in Severe Congestive Heart Failure,” sponsored by Eli Lilly and Company.

1989-1990           Principal Investigator: “Prospective Randomized Milrinone-1064 Survival Evaluation (PROMISE),” sponsored by Sterling Research Group.

1989-1992           Co-Investigator: “Thrombolysis in Myocardial Infarction (TIMI): Phase III. Funded by the National Institute of Health.

1989-1992           Co-Investigator: “A Multicenter, Prospective, Randomized, Placebo-Controlled Trial of Activase and Heparin in Patients with Unstable Angina,” sponsored by Genentech, Inc.

1990-1993           Co-Investigator: “Intravenous Triiodothyronine (T3) Therapy for Heart Donors and Recipients. CY-101,” sponsored by SmithKline Beecham Pharmaceuticals.

1991-1993           Co-Investigator: “Pathobiology of Human Heart Allograft Arteriopathy” a study in conjunction with the University of Nebraska. Funded by the National Institute of Health. #RFA88-HL-18-H.

1991-1993           Principal Investigator: “The Treatment of Class III-IV Congestive Heart Failure with Intravenous Prostaglandins (Flolan),” sponsored by Burroughs-Wellcome, Inc.

1991-1994           Principal Investigator: “Effectiveness of Antihypertensive Therapy in Cardiac Transplant Hypertension,” a study by the Working Group of Transplant Cardiologists.

1991-1994           Co-Investigator: “Thrombolysis in Myocardial Infarction (TIMI 5 – Open Label)” sponsored by Ciba-Geigy, Inc.

1991-1994           Co-Investigator: “The GRAFT Study (Graft Reperfusion After Thrombolysis): A Randomized Trial of Urokinase and t-PA for Intragraft Thrombus and Myocardial Ischemia: A Multicenter Trial,” sponsored by Genentech, Inc.

1991-1994           Co-Investigator: “Telemetric Monitoring of Endocardial Electrocardiogram Summated Voltage to Diagnosis CardiacAllograft Rejection,” sponsored by Medtronic, Inc.

1991-1994           Co-Investigator: “DEFIBRILAT – Defibrillator Implantation as Bridge to Later Transplantation,” sponsored by Cardiac Pacemakers, Inc.

1991-1995           Co-Investigator: “Usefulness of Temporary DDD Pacing with an Abbreviated AV Delay in Patients with End Stage Idiopathic Dilated Cardiomyopathy,” sponsored by Medtronic, Inc.

1992-1993           Principal Investigator: “Flolan in Severe Congestive Heart Failure: A One-Year Mortality Trial,” sponsored by Burroughs-Wellcome Company.

1992-1993           Principal Investigator: “A Dose-Range Finding Study of Intravenous 349U85 in Patients with Congestive Heart Failure,” sponsored by Burroughs-Wellcome Company.

1993-1994           Principal Investigator: “A Six-Month, Double-Blind, Placebo Controlled, Multicenter, Dose-Ranging Comparison of Oral Carvedilol in Patients with Congestive Heart Failure, NYHA Class II-IV,” sponsored by the SmithKline Beecham Company.

1993-1994           Principal Investigator: “National Study of Dobutamine Dosing Regimens in Patients with Heart Failure Receiving Home Inotropic Therapy,” sponsored by the Cardiac Alliance Corporation.

1993-1994           Principal Investigator: “A Six-Month Double-Blind, Multicenter Comparison of Oral Carvedilol bid with Placebo in Patients with Severe Congestive Heart Failure, NYHA Class III-IV,” sponsored by the SmithKline Beecham Pharmaceuticals.

1993-1994           Principal Investigator: “A Twelve Month, Double-Blind, Multicenter Comparison of Oral Carvedilol bid with Placebo in Patients with Mild Heart Failure, NYHA Class II,” sponsored by the SmithKline Beecham Pharmaceuticals.

1993-1994           Principal Investigator: “Intravascular Ultrasound Assessment of Coronary Artery Disease in Cardiac Transplant Recipients,” sponsored by the Cardiovascular Imaging Systems, Inc.

1993-1997           Co-Investigator: “Efficacy of Bronchoalveolar Lavage Flow Cytometry in the Diagnosis of Acute Lung Rejection,” sponsored in part by Sandoz Pharmaceuticals.

1993-1997           Co-Investigator: “A Randomized, Double-Blind Study to Compare the Safety and Efficacy of Fixed Low Doses of Coumadin Plus Aspirin to Aspirin Alone in the Prevention of Reinfarction, Cardiovascular Death, and Stroke in Post Myocardial Infarction Patients,” sponsored by the DuPont Merck Pharmaceutical Company.

1994-1994           Principal Investigator: “Impact of Cyclosporine on Development of Allograft Coronary Artery Disease,” sponsored by Sandoz Pharmaceuticals Corporation .

1994-1995           Principal Investigator: “A One Year Open-Label, Multicenter, Safety Study of Twice Daily Oral Carvedilol in Patients with NYHA Class I-IV Congestive Heart Failure,” sponsored by SmithKline Beecham Pharmaceuticals.

1994-1995           Principal Investigator: A Phase I/II Double-Blind, Randomized, Placebo-Controlled Ascending Dose Study of the Hemodynamic and Renal Effects of a Single Intravenous Bolus of Natrecor™ hBNP in Subjects with Congestive Heart Failure,” sponsored by Scios Nova, Incorporated.

1994-1995           Principal Investigator: “A Randomized Multiple Dose Study of the Chronic Administration of Vesnarinone (OPC-8212) in Heart Failure. Protocol #22-92-206,” sponsored by Otsuka America, Inc.

1994-1995           Principal Investigator: “A Randomized, Double Blind, Placebo- controlled, Dose Response Study to Assess the Safety and Efficacy of Oral Rapamycin in the Treatment of Acute Grade 2 or Grade 3A Cardiac Allograft Rejection,” sponsored by Wyeth-Ayerst, Inc.

1994-1998           Co-Investigator: “Novacor N100 Left Ventricular Assist System with Portable Controllers,” funded by the National Institute of Health.

1994-1997           Principal Investigator: Randomized, Double-Blind Comparative Study of Mycophenolate Mofetil or Azathioprine Each in Combination with Cyclosporine and Corticosteroids for the Prevention Cardiac Allograft Recipients,” sponsored by Syntex Pharmaceutical, Inc.

1995-1996           Principal Investigator: “Open Label Safety and Tolerability Study of Stable Cardiac Transplant Patients Converted from Cyclosporine to Neoral,” sponsored by Sandoz Pharmaceuticals, Corporation.

1995-1996           Principal Investigator: “A Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Acute and Chronic Efficacy and Safety of OPC-18790 in the Treatment of Patients with Congestive Heart Failure,” sponsored by Otsuka America, Inc.

1995-1996           Principal Investigator: “A Randomized, Double-blind, Placebo controlled, Multiple Dose Study of the Chronic Administration of Vesnarinone in Heart Failure Protocol #22-94-201,” sponsored by Otsuka America, Inc.

1995-1997           Principal Investigator: “A Phase III, Randomized, Double-Blind, Long-Term Continuation Study of OPC-18790 in Patients with Decompensated Heart Failure,” sponsored by Otsuka America, Inc.

1995-1997           Principal Investigator: “A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Effects of a 24-hour Course of Natrecor® hBNP Administered as an Intermittent Intravenous Bolus in Subjects with Congestive Heart Failure,” sponsored by Scios Nova, Inc.

1995-1997           Principal Investigator: “Multicenter, Randomized Study of the Acute and Long-Term Hemodynamic Effects and Safety of the Angiotensin II Receptor Antagonist Irbesartan (SR47436 *BMS 186295) in the Treatment of Heart Failure,” sponsored by Bristol-Myers Squibb Company.

1995-1997           Principal Investigator: “An Open Multiple Dose Study of the Chronic Administration of Vesnarinone (OPC 8212) in Heart Failure Protocol #22-95-209,” sponsored by Otsuka America, Inc.

1997-2000           Principal Investigator: “Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure,” sponsored by Sanofi Pharmaceuticals, Inc.

1998-2001           Principal Investigator: “REMATCH Trial (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure),” funded by National Institute of Health.

1998-2003           Principal Investigator: “A Two-Year, Randomized, Multicenter, Double-Blind Study of the Efficacy and Safety of SDZ RAD versus Azathioprine as Part of a Triple Immunosuppressive Therapy Regimen in de nove Heart Transplant Recipients,” sponsored by Novartis Pharmaceuticals Corp.

1999-2001           Principal Investigator: “Multicenter, Double-Blind, Randomized, Placebo Controlled, Phase II, III Study of the Effect of Recombinant Human Necrosis Factor Receptor (p75) FcFusion Protein (TNFR:Fc) (etanercept) on Clinical Improvement in Patients with Chronic Heart Failure (RENAISSANCE Study),” sponsored by Immunex Corporation.

2000 – 2004         Principal Investigator: “Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial” N01-HV-98177, funded by the National Institute of Health.

2001 – 2003         National Principal Investigator: “A Randomized Prospective, Multi-Center Comparision of Prograf, Cellcept and Steroids vs Cyclosporine (Modified USP) Cellcept and Steroids vs. Prograf, Rapamune and Steroids in DeNovo Cardiac transplant Recipients,” sponsored by Fujisawa Healthcare, Inc.

2001 – 2004         Co-Principal Investigator: “Clinical Evaluation of Acorn Cardiac Support Device Therapy in Patients with Dilated Cardiomyopathy,” sponsored by Acorn Cardiovascular, Inc.

2001 – 2004         Principal Investigator: “Randomized Multicenter Evaluation of Intravenious Levosimendan Efficacy vs Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure Revive (REVIVE),” sponsored by Orion Corporation.

2001 – 2004         Co-Principal Investigator: “The Heartmate VE LVAS Cardiogenic Shock Complicating an Acute Myocardial Infarction Trial,” sponsored by Thoratec Corporation.

2001 – 2004         Principal Investigator: “Assessment of Myocardial Recovery after Left Ventricular Assist Device Implantation” LVAD Working Group

2001 – 2002         Co-Principal Investigator: “The MYOCOR Myosplint Feasibility Study,” sponsored by Myocor, Inc.

2001 – 2003         National Principal Investigator: “A 12-Month, Single-Blind, Randomized, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of ERL080A Compared with MMF in De Novo Heart Transplants,” sponsored by Novartis Pharmaceuticals Corporation.

2002 –                      Principal Investigator: “Multidisciplinary Study of Right Ventricular Dysplasia,” funded by the National Institute of Health.

2002 –                      Co-Investigator: “ACTION: A CHF Trial Investigating Outcomes of Exercise Training,” funded by the National Institute of Health.

2003 –                      Principal Investigator: “Study to Identify the Cellular and Molecular Details of Myocardial Dysfunction and the Gene(s) that Contribute to the Dysfunction of the Failing Heart.”

2003 – 2004         Principal Investigator: “Randomized Trial of Prograf and Cell Cept vs. Cyclosporin and Cell Cept vs. Prograf plus Rapamycin in Heart Transplant Patients,” sponsored by Fujisawa Corporation.

2003 – 2005         Principal Investigator: “A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Effects of Immune Modulation Therapy (IMT) on Mortality and Morbidity in Patients with Chronic Heart Failure” (ACCLAIM),” sponsored by Vasogen, Inc.

2003 – 2005         Co-Investigator: “A Randomized Trial Comparing Outcomes of Ultrafiltration (drop in weight after 24 hours) to Standard Diuretic Therapy,” sponsored by CHF Solutions Filtration System.

2003 – 2005         Co-Investigator: “A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Impact of Subcutaneous Darbepoetin Alfa Treatment on Exercise Tolerance in Subjects with Symptomatic Congestive Heart Failure and Anemia. Phase 2,” sponsored by Amgen, Inc.

2003 – 2005         Co-Investigator: “A Randomized, Double-blind, Placebo-controlled, Dose-ranging Pilot Study Evaluating the Efficacy and Safety of YM087 in Patients with Decompensated Chronic Heart Failure,” sponsored by Yamanouchi/Omnicare.

2004 – 2005         National Principal Investigator: “Use of LVAD for Cardiogenic Shock in Patients with Acute Myocardial Infarction,” sponsored by Thoratec Corporation.

2004 -2007          Principal Investigator: “IMAC II: Genetic Modulation of LV Recovery,” funded by the National Institute of Health

  • Site PI: SCCOR grant Mount Sinai School of Medicine. Use of Mesenchymal Stem Cells for Cardiac Recovery in Patients on LVAD as Bridge to Transplant.   PI: Eric Rose

2008                      Site Principal Investigator: Heartware LVAD for Patients with refractory HF as a Bridge to Transplant Heartware Corporation

2008:                     Site PI: NHLBI SCOR grant on use of Allogeneic Mesenchymal Cells for advanced HF in patients supported with an LVAD.

2010-2012          Site PI: Use of Neuregulin gene therapy for advanced HF. Zensun Corp

2010-2013          National PI for Juventas JVS-100 Study of SDF gene therapy in ischemic HF.

2011- 2013         Site PI: Use of SDF-1 gene therapy for patients with HF: Juventas Corp

2011-2012          Site PI for CUPID gene therapy with SERCA-2a for HF: Celladon Corp

2012-2013           Site PI for ATHENA trial of Adipose Derived Regenerative Cells in Ischemic HF.

Cytori Corporation

  • Site Co-PI MEDAMACS NHLBI supported Registry to identify risk factors in patients with    advanced HF

2014-                     Study PI for Mesoblast –Teva DREAM study of Allogeneic Stem Cell Trial for Heart Failure

Books As Editor

  1. Miller, LW, Perin E, Willerson JT.   Stem Cell and Gene Therapy for Cardiovascular Disease, Elsevier Publishers, Philadelphia, PA. Expected publication Sept, 2015
  2. Kormos RL, Miller L (editor) Braunwald Companion on Mechanical Circulatory Support. Elsevier Publishers, Philadelphia, PA. 2011
  3. Miller LW, Freitag JJ (editor): Manual of medical therapeutics, 23rd edition, Little, Brown and Company, Boston, 1980.
  4. Miller LW, (associate editor): Intensive review of cardiovascular disease, Harvard Medical School, Department of Continuing Education, Boston, 1981
  5. Emery RE, Miller, LW. Handbook of Cardiac Transplantation.(Hanley and Belfus, Philadelphia, 1996)
  6. Cooper, DK, Miller LW, Patterson GA. Assoc Editor). The Transplantation and Replacement of Thoracic Organs. The Present Status of Biological and Mechanical Replacement of the Heart and Lungs. Second Edition. Cooper DK, (eds). (Kluwer Academic Publishers) 1988

Book Chapters as Author

  1. Miller, LW. Stem Cell Homing. In above textbook on Stem Cell and Gene Therapy
  2. Miller, LW. Stem Cell Therapy for Acute Myocardial Infarction
  3. Miller, LW. Multiple Dosing of stem cell and gene therapy in above textbook.
  4. Miller, LW. Patient Selection for MCS in above textbook on MCS
  5. Swartz MT, Pennington DG, McBride LR, Miller LW, Reedy JE, Kanter KR, Taub J. Temporary Mechanical Circulatory Support: Clinical experience with 148 patients. In: Assisted Circulation 3 (Chapter 11); Unger, F. (ed.) Third edition, Springer-Verlag Berlin Heidelberg; 1989: pp 132-51.
  6. Pennington DG, Swartz MT, McBride LR, Kanter KR, Miller LW: Selection of circulatory support devices. Bulletin of the Minneapolis Heart Institute Foundation, 1989.
  7. Pennington DG, Swartz MT, McBride LR, Reedy JE, Miller LW: Bridging to cardiac transplantation with circulatory support devices. Artificial Heart. 3 – Heart Replacement (Chapter 35); Akutsu T, Koyanagi H (eds.). Springer -Verlag Tokyo; 1991: pp 293-301.
  8. Miller LW: Candidate selection for heart transplantation. Cardiology Clinics. Advanced treatment options for the failing left ventricle; Elefteriades JA, Lee FA, Letsou GV (eds) 1995;13(1). W.B. Saunders Co. 1995:pp 93-100.
  9. Emery RW, Miller LW (editors): Handbook of Cardiac Transplantation. Hanley & Belfus, Inc. Philadelphia (publishers) Mosby, St. Louis. 1995 pp: 1-289.
  10. Miller LW, Yip D, Scott R, Donohue T, Wolford T. Candidate selection in cardiac transplantation. Loh E (ed.) (W.B. Saunders Co, 1996).
  11. Miller LW. Heart transplantation. Critical Care, Third Edition. Civetta JM, Kirby RR, Taylor RW (eds.). (Lippincott-Raven, Philadelphia, October, 1996), Chapter 88;pp1-21.
  12. Miller L. The treatment of cardiac allograft rejection. The Transplantation and Replacement of Thoracic Organs. The Present Status of Biological and Mechanical Replacement of the Heart and Lungs. Second Edition. Cooper DK, Miller LW, Patterson GA (eds). (Kluwer Academic Publishers
  13. Miller LW, Donohue T, Wolford T, Drury J. Diagnosis and treatment of allograft coronary disease. The Transplantation and Replacement of Thoracic Organs. The Present Status of Biological and Mechanical Replacement of the Heart and Lungs. Second Edition. Cooper
  14. Miller LW, Wolford TL, Donohue T, Jennison SH: Steroid withdrawal in cardiac transplantation. In Handbook of Cardiac Transplantation. Emery RW, Miller LW (Hanley and Belfus, Philadelphia, 1996), Chapter 10; pp 103-108.
  15. Halloran PF, Lui SL, Miller LW. Review of Transplantation – 1996. Clinical Transplants 1996.
  16. Cooper DKC, Miller LW, Patterson AC. The Transplantation and Replacement of Thoracic Organs. Kluwer Academic Publishers, Boston. Released April, 1997, 825 pages.
  17. Miller LW. Should immunosuppression be reduced over time? Yearbook of Transplantation. Livi U (ed). Chapter 6. P 69-88. 1997.
  18. Miller LW, Wolford TL, Donohue T: Non-specific graft dysfunction in cardiac transplantation. In Handbook of Cardiac Transplantation. Emery RW, Miller LW (Hanley and Belfus, Philadelphia, 1997), Chapter 13; pp 129-134.
  19. Miller LW, Wolford TL, Donohue T: Allograft coronary disease. In Handbook of Cardiac Transplantation. Emery RW, Miller LW (Hanley and Belfus, Philadelphia, 1997), Chapter 14; p135-140. 1998
  20. Miller LW, Miller EM. Allograft Coronary Artery Disease. Handbook of Cardiac Transplantation,
  21. Miller LW, Lietz K. Heart transplantation: indications, outcome, and long term complications. In: Willerson, JT, ed. Cardiovascular Medicine, 2nd W.B. Saunders Co; 2005.
  22. Miller LW, Lietz K. Cardiac transplantation: pathogenesis, immunosuppression, and diagnosis and treatment of rejection. In: Willerson, JT, ed. Cardiovascular Medicine, 2nd W.B. Saunders Co; 2005.
  23. Miller LW, Young JB. Physiology of the transplanted heart. In: Norman D, Suki W, eds. Primer on Transplantation. Mt. Laurel, NJ 1997:435-437.
  24. Miller LW. Action, Efficacy & Toxicities: Tacrolimus. In: Norman D, Suki W, eds. Primer on Transplantation, 2nd Mt. Laurel, NJ: American Society of Tranplant Physicians; 2001:130-137.
  25. Miller LW, Granville DJ, Narula J, McManus BM. Apoptosis in Cardiac Transplant Rejection. In: Narula J, Dixit VM, Miller LW, eds. Cardiology Clinics: Apoptosis in Cardiovascular Disease, Philadelphia, PA. W.B. Saunders Co; 2001:141-154.
  26. Miller LW, Missov ED. Epidemiology of Heart Failure. In: Young JB, ed. Cardiology Clinics: Heart Failure, Philadelphia, PA: W.B. Saunders Co; 2001:547-555.
  27. Lietz KL, Miller LW. Patient Selection for Left Ventricular Assist Devices. Current Opinion in Cardiology. Nov, 2008:34: 213-222.
  28. Miller LW. Patient selection for mechanical circulatory support for advanced heart failure. Braunwald companion Mechanical Circulatory Support. Philadelphia, PA: Elsevier Co. Chapter 6. Pages 72-88
  29. Miller LW, Young JB. Acute Decompensated Heart Failure. Braunwald companion Mechanical Circulatory Support. Philadelphia, PA. Elsevier Co. Chapter 3, pages 22-42
  30. Birks EM, Miller LW. Myocardial recovery with use of ventricular assist devices. Braunwald companion on Mechanical Circulatory Support. Philadelphia, PA. Elsevier Co

 

MANUSCRIPTS:           

  1. Miller LW, Labovitz AJ, Kennedy HL: Mechanical complications of acute myocardial infarction. Cardiovas Res and Reports 1984;5:948-62.
  2. Miller LW, Codd JE, Sarafian JE, Pennington DG, Willman VL: Heart transplantation at St. Louis University School of Medicine. J Heart Transplant 1984;IV (1):30.
  3. Pennington DG, Merjavy JP, Codd JE, Swartz MT, Miller LW, Williams GA: Extracorporeal membrane oxygenation for patients with cardiogenic shock. Circulation 1984;70:130-7.
  4. Miller LW, Jellinek M, Codd JE, Kolata R: Improved myocardial preservation with machine perfusion. J Heart Transplant 1985;4(3):319-24.
  5. Palmer DC, Codd JE, Miller LW, Roodman ST, Tsai CC, Williams GA: Accelerated graft arteriosclerosis: an ominous finding on endomyocardial biopsy of transplanted heart. Transplantation 1985;39:385-8.
  6. Miller LW: Role of intra-aortic balloon pump in the treatment of ischemic heart disease. Cardiac Assists 1986;3(1):4-11.
  7. McBride LR, Pennington DG, Miller LW, Kanter KR, Sarafian JE, Willman VL: Heart transplantation at St. Louis University Medical Center. J Heart Transplant 1986;5:47.
  8. Kanter KR, Pennington DG, McBride LR, Miller LW, Swartz MT, Naunheim KS, Willman VL: Mechanical circulatory assistance following heart transplantation. J Heart Transplant 1987;6(3):May/June, 150-55.
  9. Lewen MK, Bryg RJ, Miller LW, Labovitz AJ, Williams GA: Tricuspid regurgitation by Doppler echocardiography following orthotopic cardiac transplantation. Am J Cardiol 1987;59:1371-74.
  10. McBride LR, Ruzevich SA, Pennington DG, Kennedy DJ, Kanter KR, Miller LW, Termuhlen DF: Infectious complications associated with ventricular assist device support. Trans Am Soc Artif Intern Organs 1987;33:201-2.
  11. Kanter KR, Swartz MT, Pennington DG, McBride LR, Miller LW, Ruzevich SA: Emergency extracorporeal membrane oxygenation (ECMO) for cardiopulmonary resuscitation. J Heart Trans 1987;5(5):396-401.
  12. Miller LW, Labovitz AJ, McBride LR, Pennington DG, Kanter K, Habermehl K, Nelson J, Mrosek D: Echocardiography-guided endomyocardial biopsy: A 5 year experience. Circulation 1988;78(5) suppl:III-99-III-103.
  13. Miller LW, Noedel NV, Pennington DG, McBride L, Kanter KR: Cardiac transplantation in patients over 55 years of age. J Heart Transpl 1988;7(4):254-7.
  14. Miller LW, Kennedy DJ, Pennington DG, McBride LR: Incidence and clinical course of cytomegalovirus in cardiac transplant patients without the use of antilymphocyte sera. J Heart Transpl.
  15. Roodman ST, Miller LW, Tsai CC: Role of IL-2 receptors in immunologic monitoring following cardiac transplantation. Transplantation 1988;45(6):1050-56.
  16. Roodman ST, Tsai CC, Miller LW: Correlation of the CD4 Interleukin-2 receptor positive cells in the peripheral blood with rejection in human transplant recipients. Trans Proc 1988;3(3):1068-71.
  17. Pennington DG, McBride LR, Kanter KR, Swartz MT, Miller LW: The effect of perioperative myocardial infarction on survival of postcardiotomy patients supported with ventricular assist devices. Circulation 1988;78 (Suppl III):III-110-III-115.
  18. Kanter KR, McBride LR, Pennington DG, Swartz MT, Ruzevich SA, Miller LW, Willman VL: Bridging to cardiac transplantation with pulsatile ventricular assist devices. Ann Thorac Surg 1988;46:133-9.
  19. Pennington DG, Kanter KR, McBride LR, Kaiser GC, Barner HB, Miller LW, Naunheim KS, Willman VL: Seven years experience with the Pierce-Donachy ventricular assist device. J Thorac Cardiovasc Surg 1988;96(6):901-11.
  20. Miller LW: Allograft coronary artery disease. Heart Failure 1989;5:253-9.
  21. Pennington DG, McBride LR, Kanter KR, Miller LW, Ruzevich SA, Naunheim KS, Swartz MT, Termuhlen DF: Bridging to heart transplantation with circulatory support devices. J Ht Trans 1989;8(2)116-123.
  22. Pennington DG, McBride LR, Kanter KR, Kaiser GC, Barner HB, Miller LW, Naunheim KS, Fiore AC, Willman VL: Use of the Pierce-Donachy ventricular assist device in patients with cardiogenic shock after cardiac operations. Ann Thorac Surg 1989;47(1):130-57.
  23. Labovitz AJ, Drimmer A, Miller LW, McBride LR: Exercise capacity during the first year after cardiac transplantation. Am J Cardiol 1989;64:642-45.
  24. Swartz MT, Pennington DG, Ruzevich SA, McBride LR, Miller LW, Reedy JE, Termuhlen DF: The incidence of isolated left ventricular failure in bridge-to-transplant candidates. Trans Am Soc Artif Intern Organs 1989;35(3)730-33.
  25. Termuhlen DF, Pennington DG, Roodman ST, Ruzevich SA, Swartz MT, Reedy JE, McBride LR, Miller LW, Tsai CC, Kennedy DJ: T cells in ventricular assist device patients. Circulation 1989;80(suppl III):III-174-III-182.
  26. McBride LR, Pennington DG, Miller LW: Axillary artery insertion of an intra aortic balloon pump. Ann Thorac Surg 1989;48:874-5.
  27. Raithel SC, Swartz MT, Braun PR, Dake SB, Taub JO, Zambie MA, Miller LW, et al: Experience with an emergency resuscitation system. ASAIO Transactions 1989;35:475-77.
  28. Miller LW, Merkle EJ, Herrmann V: Outpatient ambulatory dobutamine for end stage congestive heart failure. Crit Care Med 1990;18(1):S30-S33.
  29. Miller LW, Pennington DG, McBride LR: Long-term effects of cyclosporine in cardiac transplantation. Trans Proc 1990;22(3);Suppl 1:15-20.
  30. Miller LW: Treatment of cardiac allograft rejection with intravenous corticosteroids. J Heart Transplant; 1990;9:283-7.
  31. Seacord LM, Miller LW, Pennington DG, McBride LR, Kern MJ: Reversal of constrictive/restrictive physiology with treatment of allograft rejection. Am Heart J 1990;120(2):455-9.
  32. Reedy JE, Swartz MT, Termuhlen DF, Pennington DG, McBride LR, Miller LW, Ruzevich SA: Bridge to cardiac transplantation: importance of patient selection. J Heart Trans 1990;9(5):473-81.
  33. Szukalski EA, Reedy JE, Pennington DG, Swartz MT, McBride LR, Miller LW: Oral anticoagulation in patients with ventricular assist devices. ASAIO Trans 1990;36(3):700-3.
  34. Lohmann DP, Swartz MT, Pennington DG, McBride LR, Reedy JE, Miller LW: Left ventricular vs. left atrial cannulation for the Thoratec ventricular assist device. Trans Am Soc Artif Intern Organs, 1990
  35. Seacord LM, Miller LW. Pennington DG, McBride LR, Kern MJ. Reversal of constrictive/restrictive physiology with treatment of allograft rejection. American Heart Journal 1990;120(2):455-9.
  36. Miller LW: Outpatient Dobutamine for refractory congestive heart failure: advantages, technique, and results. J Heart & Lung Transplant 1991;10(3):482-7.
  37. Miller LW: Introduction. Management of congestive heart failure pre-transplant. Proceedings of a symposium presented at the 10th Annual Meeting & Scientific Sessions of the International Society for Heart Transplantation. Fort Lauderdale, Florida, April, 1990, J Heart & Lung Transplan1991;10(3):467.
  38. Miller LW: Long term complications of cardiac transplantation – An Invited Review. Prog Cardiovasc Dis 1991;33(4):229-82.
  39. Miller LW, Phelan DL, Noedel N, McBride LR, Pennington DG: Multiparous women: is routine antibody screening enough in cardiac transplantation? Transplant Proc 1991;23(1):1135-6.
  40. Miller LW: Mechanical assist devices in intensive cardiac care. Am Heart J 1991; 121(6):1887-92.
  41. Gollub SB, Elkayam U, Young JB, Miller LW, Haffey KA: Efficacy and safety of a short-term (6 hour) intravenous infusion of Dopexamine in patients with severe congestive heart failure: A randomized, double-blind, parallel, placebo controlled multicenter study. J Am Coll Cardiol 1991;18:383-90.
  42. Kern MJ, Deligonul U, Miller LW: Hemodynamic rounds: Interpretation of cardiac pathophysiology from pressure waveform analysis. IV. Extra hearts: Part I. Catheterization & Cardiovascular Diagnosis 1991;22:197-204.
  43. Pennington DG, Reedy JE, Swartz MT, McBride LR, Seacord LM, Naunheim KS, Miller LW: Univentricular versus biventricular assist device support. J Heart & Lung Transplant 1991;10(2):258-63.
  44. Appleton SR, Miller LW, Nouri S, Pennington DG, Bunchman TE: Endomyocardial biopsies in pediatric patients with no irradiation: use of internal jugular venous approach and echocardiographic guidance. Transplantation 1991;51(2):309-11.
  45. Warner-Stevenson L, Miller LW: Cardiac transplantation as therapy for heart failure. Current Problems in Cardiology 1991;16(4)219-305.
  46. Packer M, Carver JR, Chesebro JH, Ivanhoe RJ, Miller LW, et al and the PROMISE Study Investigators and Coordinators: Effect of ORAL Milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75.
  47. Canter CE, Appleton RS, Saffitz JE, Bologna S, Miller L, Pennington DG, Spray TL: Surveillance for rejection by echocardiographically guided endomyocardial biopsy in the infant heart transplant recipient. Circulation 1991;84 (Suppl III):III-310-III-315
  48. Miller LW. Mechanical assist devices in intensive cardiac care. Am Heart J 1991;121(6 pt 1):188:92.
  49. Miller LW: Steroid withdrawal. An editorial of the proceedings of the Steroid Withdrawal Symposium, October 25, 1991, St. Louis, Missouri. J Heart & Lung Transplant 1992;11(2):401-2.
  50. Miller LW, Wolford T, McBride LR, Peigh P, Pennington DG: Successful withdrawal of corticosteroids in heart transplantation. J Heart & Lung Transplant 1992;11(2):431-4.
  51. Miller LW. Transplant coronary artery disease. An editorial of the proceedings of the Transplant Coronary Artery Disease Symposium, October 25, 26, 1991, St. Louis, Missouri. J Heart & Lung Transplant 1992;11:S1-S4.
  52. Miller LW. Allograft vascular disease: A disease not limited to hearts. J Heart & Lung Transplant 1992;11:S32-S37.
  53. Reedy JE, Pennington DG, Miller LW, McBride LR, Lohmann DT, Noedel NR, Swartz MT: Status I heart transplant patients conventional vs ventricular assist device (VAD) support. J Heart Lung Transplant 1992;11:246-52.
  54. Donohue T, Aguirre F, Miller L, Kern M: Angiographic and intracoronary flow velocity reversal in a transplanted heart: A common etiology for an uncommon condition. Am Heart J 1992;123(5):1374-7.
  55. Donohue T, Kern MJ, Wolford T, Bach R, Aguirre F, Miller L: The effects of epicardial coronary spasm on intracoronary flow velocity and pressure gradient in a patient after cardiac transplantation. Am Heart J 1992;124:1645-8.
  56. Dressler FA, Miller LW: Necropsy versus angiography: how accurate is angiography? J Heart Lung Transplant 1992;11(3):S56-9.
  57. Kendall TJ, Wilson JE, Radio SJ, Kandolf R, Gulizia JM, Winters GL, Costanzo-Nordin MR, Malcom GT, Thieszen SL, Miller LW, McManus BM: Cytomegalovirus and other herpes viruses: Do they have a role in the development of accelerated coronary arterial disease in human heart allografts? J Heart Lung Trans 1992;11(3):S14-S20.
  58. Ensley RD, Hunt S, Taylor DO, Renlund DG, Menlove RL, Karwande SV, O’Connell JB, Barr ML, Michler RE, Copeland JG, Miller LW and the Registry of the International Society for Heart and Lung Transplantation and contributing investigators: Predictors of survival after repeat heart transplantation. J Heart Lung Transplant 1992;11(3):142-58.
  59. Miller LW, Wesp A, Jennison SH, Graham MA, Martin TW, McBride LR, Pennington DG, Peigh P. Vascular rejection in cardiac transplant recipients. J Heart Lung Transplant 1993;12(2):S147-S152.
  60. Miller LW. Vascular rejection. An editorial of the proceedings of a symposium held before the 1992 annual meeting of the International Society for Heart and Lung Transplantation, April 1, 1992, San Diego, California. J Heart Lung Transplant 1993;12(2):S111-S112.
  61. Miller LW, Kobashigawa J, Kubo SH, Renlund DG. 24th Bethesda Conference. Cardiac transplantation. Task Force 5. Complications. J Am Coll Cardiol 1993;22(1):41-54 (July).
  62. Ohar J, Osterloh J, Ahmed N, Miller L: Diffusing capacity decreases after hear

transplantation. Chest 1993;103:857-61.

  1. Bell C, Kern MJ, Aguirre F, Miller LW, Bach R, Donohue T, Dressler F: Coronary atherectomy complicated by coronary embolus in a cardiac transplant recipient. Am Heart J April 1993;125(4):1172-5.
  2. Jennison SH, Miller LW, Wesp AG: Cytokines and acute cardiac rejection – the unfulfilled promise? Letter to the Editor. J Am Coll Cardiol 1993;22(4).
  3. Kobashigawa JA, Kirklin JK, Naftel DC, Bourge RC, Ventura HO, Mohanty PK, Cintron GB, Bhat G, Miller LW, and the Transplant Cardiologists Research Database Group: Pretransplantation risk factors for acute rejection after heart transplantation: a multiinstitutional study. J Heart Lung Transplant 1993;12(3):355-366.
  4. Jennison SH, Miller LW: What to try while congestive heart failure patients are still ambulatory. [Review]. Postgraduate Medicine 1993;94(5):66-8t.
  5. Bourge RC, Naftel DC, Costanzo-Nordin MC, Kirklin JK, Young JB, Kubo SH, Olivari MT, Kasper EK, Miller LW and the Transplant Cardiologists Research Database Group: Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study. J Heart Lung Transplant 1993;12(4)July:549-563.
  6. Miller LW, Naftel DC, Bourge RC, Kirklin JK, Brozena SC, et al and the Cardiac Transplant Research Database Group. Infection following cardiac transplantation: a multi-institutional study. J Heart Lung Transplant 1994;13:381-93.
  7. Miller LW. Optimal use of Cyclosporine in cardiac transplantation. Transplantation Proceedings 1994;26(5):2700-03. (October)
  8. Miller LW, Merkle EJ, Jennison SH. Outpatient use of dobutamine to support patients awaiting heart transplantation. J Heart Lung Transplant 1994;13(4):S126-S129.
  9. Pennington DG, McBride LR, Peigh PS, Miller LW, Swartz MT: Eight years experience with bridging to cardiac transplantation. J Thorac Cardiovasc Surg 1994;107:472-81.
  10. Pennington DG, McBride LR, Miller LW, Swartz MT: Eleven years experience with the Pierce-Donachy ventricular assist device. J Heart Lung Transplant 1994;13(5):803-810. (September, 1994).
  11. Jennison SH, Wesp A, McBride L, Miller L. Limited utility of early trough cyclosporine level monitoring to predict the rate of acute rejection in the first three months after cardiac transplantation. Transplant Proceed 1994;26(5):2732-5.
  12. Young JB, Naftel DC, Bourge RC, Kirklin JK, Clemson BS, Porter CB, Rodeheffer RJ, Kenzora JL, Miller LW and the Cardiac Transplant Research Database Group: Matching the heart donor and heart transplant recipient. Clues for successful expansion of the donor pool: a multivariable, multiinstitutional report. J Heart Lung Transplant 1994;13:353-65.
  13. Kirklin JK, Naftel DC, Levine TB, Bourge RC, Pelletier GB, O’Donnell J, Miller LW, Pritzker MR and the Cardiac Transplant Research Database Group: Cytomegalovirus after heart transplantation: risk factors for infection and death; a multi-institutional study. J Heart Lung Transplant 1994;13:394-404.
  14. Jarcho J, Naftel DC, Shroyer TW, Kirklin JK, Bourge RC, Barr ML, Pitts DG, Starling RC, Miller LW and the Cardiac Transplant Research Database Group. Influence of HLA mismatch on rejection after heart transplantation: a multiinstitutional study. J Heart Lung Transplant 1994;13:583-96.
  15. Miller LW, Kubo SH, Young JB, Stevenson LW, Loh E, Costanzo MR. Report of the Consensus Conference: Candidate selection for cardiac transplantation. J Heart Lung Transplant 1995;14(3):562-71.
  16. Miller LW. The role of intracoronary ultrasound for the diagnosis of cardiac allograft vasculopathy. Transplantation Proceedings 1995;27(3):1989-92.
  17. Miller LW, Wolford TL, Donohue TJ, Drury JH. Cardiac allograft vasculopathy: New insights from intravascular ultrasound and coronary flow measurements. Transplantation Reviews 1995;9(2):77-96.
  18. Miller LW, Kobashigawa J, Valantine H, Ventura H, Hauptman P, O’Donnell J, Wiedermann J, Yeung A. The impact of cyclosporine dose and level on the development and progression of allograft coronary disease. J Heart Lung Transplant 1995;14(6):S227-S233.
  19. Kemp DL, Jennison SH, Stelken AM, Younis LT, Miller LW: Association of resting heart rate and chronotropic response on cardiopulmonary exercise in heart transplant recipients. Am J Cardiol 1995;75(10):751-2.
  20. Votapka TV, Swartz MT, Reedy JE, Lohmann DP, McBride LR, Miller LW, Pennington DG: Heart transplantation charges: status 1 versus status 2 patients. J Heart Lung Transplant 1995;14(2):366-72.
  21. Halle AA, Massin EK, Johnson MR, Bourge RC, Miller LW, et al: Coronary angioplasty, atherectomy, and bypass surgery in cardiac transplant patients. J Am Coll Cardiol 1995;26:120-8.
  22. Dhar SC, Miller LW. Refractory immune thrombocytopenic purpura following heart transplantation, a case report. J Heart Lung Transplant 1995;14(4):785-87 (July/August).
  23. Kubo SH, Naftel DC, Mills RM, O’Connell J, Rodeheffer RJ, Cintron GB, Kenzora JL, Bourge RC, Kirklin JK, Miller LW. Cardiac Transplant Research Database Group. Risk factors for late recurrent rejection after heart transplantation: a multiinstitutional, mutivariable analysis. J Heart Lung Transplant 1995;14(3):409-418
  24. Caracciolo EA, Wolford TL, Underwood RD, Donohue TJ, Bach RG, Miller LW, Kern MJ. Influence of intimal thickening on coronary blood flow responses in orthotopic heart transplant recipients: a combined intravascular Doppler and ultrasound imaging study. Circulation 1995;92(9 Suppl):II182-90.
  25. Keller CA, Ohar J, Ruppel G, Wittry MD, Goodgold HM, Baudendistel LJ, McBride LR, Miller LW, et al. Right ventricular function in patients with severe chronic obstructive pulmonary disease evaluated for lung transplantation. Chest 1995;107:1510-16.
  26. Miller LW. Candidate selection for heart transplantation. Cardiology Clinics.1995;13(1):93-100.
  27. Yeung AC, Davis SF, Hauptman PJ, Kobashigawa JA, Miller LW, et al,. Incidence and progression of transplant coronary artery disease over 1 year: results of a multicentre trial with use of intravascular ultrasound. Multicenter Intravascular Ultrasound Transplant Study Group. Journal of Heart & Lung Transplantation. 1995; 14(6 Pt 2):s215-20.
  28. Miller LW. Heart transplantation in the pediatric population. Kidney International 1996;49(Suppl 53):S-85-S-87.
  29. Miller LW, Donohue TJ, Wolford TL. The surgical management of allograft coronary disease: a paradigm shift. Seminars in Thoracic and Cardiovascular Surgery 1996;8(2):133-138 (April).
  30. Miller LW. Cyclosporine associated neurotoxicity: the need for a better guide for immunosuppressive therapy. Editorial. Circulation 1996;94:1209-11 (September).
  31. Halloran PF and Miller LW. In Vivo immunosuppressive mechanisms. Transplantation Immunology Forums. J Heart and Lung Transplant 1996;15(10):959-969.
  32. Hobbs RE, Miller LW, Bott-Silverman C, James KB, Rincon G, Grossbard EB. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996;78:896-90.
  33. Stelken AM, Younis LT, Jennison SH, Miller DD, Miller LW, Kargl D, Chaitman BR. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol 1996;27:345-52.
  34. Brozena S, Johnson MR, Ventura H, Hobbs R, Miller L, Olivari MT, Clemson B, et al. Effectiveness and safety of diltiazem or lisinopril in the treatment of hypertension after cardiac transplantation: results of a prospective, randomized, multi-center trial. J Am Coll Cardiol 1996;27(7):1707-12.

Dressler FA, Javier JJ, Salinas-Madrigal L, Milligan TW, McBride LR, Labovitz AJ, Miller LW. Myocardial toxoplasmosis complicating cardiac transplant. J Cardiovasc Pathol 1996;5:101-104.

  1. Kern MJ, Bach RG, Mechem CJ, Caracciolo EA, Aguirre FV, Miller LW, Donohue TJ. Variations in normal coronary vasodilatory reserve stratified by artery, gender, heart transplantation, and coronary artery disease. J Am Coll Cardiol 1996; 28(5):1154-60.
  2. Halloran PF, Lui SL, Miller LW. Review of Transplantation-1996. Clinical Transplants1996:291-319.
  3. Rodeheffer R, Naftel D, Warner-Stevenson L, Porter C, Young J, Miller L, et al. Secular     trends in cardiac transplant recipient and donor management in the United States 1990-1994: A multi-institutional study. Circulation 1996; 94(11)2883-9.
  4. Tinawi M, Miller L, Bastani B. Renal function in cardiac transplant recipients: retrospective analysis of 133 consecutive patients in single center. Clinical Transplantation 1997;11(1):1-8.
  5. Halloran PF, Goes N, Urmson J, Ramassar V, Miller LW. MHC expression in

transplants: lessons from the knock-out mice. Transplantation Proceedings 1997; 29:1041-1044.

  1. Miller LW. Allograft coronary disease: the role of antigen independent mechanisms in pathogenesis (Review). Annals of Transplantation, 1997; 2(2):61-4.
  2. Miller LW. The role of inflammation in the development of allograft coronary disease

(Review). Transplantation Proceedings, 1997; 29(6):2583-4.

  1. Osada N, Chaitman, BR, Donahue TJ, Wolford TL, Stelken AM, Miller LW. Long-term

cardiopulmonary exercise performance after heart transplantation. Am Journal of Cardiology.     1997;79(4):451-6.

  1.  Miller LW,   Allograft coronary disease: the role of antigen independent mechanisms in pathogenesis. [Review] [53 refs]. Annals of Transplantation. 1997;2(2):61-4.
  2.  Kobashigawa J, Miller L, Renlund D, Mentzer R, et al. A randomized active-controlled

trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998; 66(4);507-515.

  1. Costanzo MR, Naftel DC, Kirklin JK, Bourge RC, Miller LW. Heart transplant coronary artery disease detected by coronary angiography: a multi-institutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant, 1998, 17(8):744-53.
  2.  Miller LW. Listing criteria for cardiac transplantation: results of an Am Society of Transplant  Physicians – National Institutes of Health conference. Transplantation, 1998, 66(7):947-51.
  3. Osada N, Chaitman BR, Miller LW, Yip D, Cishek MB, Wolford TL, Donohue TJ.

Cardiopulmonary exercise testing identifies low risk patients with heart failure and severely impaired  exercise capacity considered for heart transplantation. J Am Coll Cardiol 1998;31:577-582.

  1. Miller LW. Listing criteria for cardiac transplantation: results of an American Society of Transplant    Physicians-National Institutes of Health conference. Transplantation 1998;66(7):947-51
  2. Costanzo MR, Naftel DC, Pritzker MR, Hellman JK 3rd, Boehimer JP, Brozena SC, Dec GW, Ventura HO, Kirklin JK, Bourge RC, Miller LW. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. Transplantation 1998;17(8):744-53.
  3. Osada N, Chaitman BR, Miller LW, Yip D, Cishek MB, Wolford TL, Donohue TJ. Cardiopulmonary exercise testing identifies low risk patients with heart failure and severely impaired exercise capacity considered for heart transplantation. J Am College of Cardiology 1998;3(3):577-82
  4. Rose AG, Miller LW, Shumway SJ. Status epilepticus and cardiac transplantation (letter).

Transplantation, February 1999; 67(4):640-1.

  1. Wolford TL, Donohue TJ, Bach RG, Drury JH, Caracciolo EA, Miller LW, et al.

Heterogeneity of coronary flow reserve in the examination of multiple individual allograft coronary arteries. Circulation 1999; 99:626-632.

  1. Christov A, Dai E, Liu L, Miller LW, Nash P, Lalani A. McFadden G, Tulip J, Lucas A.

Detection of transplant vasculopathy in a rat aortic allograft model by fluorescence spectroscopic optical analysis. Lasers in Surgery & Medicine 1999; 24(5):346-59.

  1. Christov A, Dai E, Liu L, Miller LW, Nash P, Lalani A, McFadden G, Nation PN, Tulip J, Lucas A. Detection of transplant vasculopathy in a rat aortic allograft model by fluorescence spectroscopic optical analysis. Lasers in Surgery & Medicine. 1999;24(5):346-59.
  2. Rose AG, Miller LW, Shumway SJ. Status epilepticus and cardiac transplantation. Transplantation 1999;67(4):640-1.
  3. Wolford TL, Donohue TJ, Bach RG, Drury JH, Caracciolo EA, Kern MJ, Miller LW. Heterogeneity of coronary flow reserve in the examination of multiple individual allograft coronary arteries. Circulation 1999;99(5):626-32.
  4. Bank A, Mir SH, Nguyen DQ, Bolman RM 3rd, Shumway SJ, Miller LW, Kaiser DR, Ormaza SM, Park SJ. Effects of left ventricular assist devices on outcomes in patients undergoing heart transplantation. Annals of Thoracic Surgery 2000;69(5):1369-74.
  5. Miller LW, Dai E, Nash P, Liu L, Icton C, Klironomos D, Fan L, Nation PN, Zhong R, McFadden G, Lucas A.        Inhibition of transplant vasculopathy in a rat aortic allograft model after infusion of anti-inflammatory viral serpin. Circulation 2000;101(13):1598-605.
  6. Miller LW, Dai E, Nash P, Liu L, Icton C, Klironomous D, Fan L, Nation PN, Zhong R,

McFadden G, Lucas A. Inhibition of transplant vasculopathy in a rat aortic allograft model after    infusion of an anti-inflammatory viral serpin. Circulation, 101(13):1598-605, 2000.

  1. Rose AG, Park SJ, Bank AJ, Miller LW. Partial aortic valve fusion induced by left ventricular assist device. Annals of Thoracic Surgery. October 2000;7(4):1270-4.
  2. Miller, LW. The Significance of acute rejection in cardiac transplantation. Graft,

January/February 2000, 3(1):27-30.

  1. Miller, LW, Dai E., Nash P, Liu L, Icton C, Klironomos D, et al. Inhibition of transplant

vasculopathy in a rat aortic allograft model after infusion of an anti-inflammatory viral serpin. Circulation 2000, 101(13):1598-1605.

  1. Bank AJ, Mir Sh Nguyen DQ, Bolman RM 3rd, Shumway SJ, Miller LW, Kaiser DR,

Ormaza SM, Park SJ. Effects of left ventricular assist devices on outcomes n patients

undergoing heart transplantation. Annals of Thoracic Surgery 2000, 69(5):1369-74;

discussion 1375.

  1. Rose AG, Park SJ, Bank AJ, Miller LW. Partial aortic valve fusion induced by left

ventricular assist device. Ann Thorac Surg 2000;70:1270-4.

  1. AJ Bank, SH Mir, DQ Nguyen, RM Bolman III, SJ Shumway, LW Miller. Effects of left ventricular assist devices on outcomes in patients undergoing heart transplantation. Annals of thoracic surgery 69 (5), 1369-1374
  2. Miller, LW, Berry, B; Missov, E. Idiopathic cardiomyopathy. Current Treatment Option

in Cardiovascular Medicine 2000; 2(5):421-430.

  1. Lucas A, Dai E, Liu L, Guan H, Nash P, McFadden G, Miller L. Transplant vasculopathy: viral anti- inflammatory serpin regulation of atherogenesis. J Heart Lung Transplant 2000; 19:1029-1038.
  2. Miller LW, Granville DJ, Narula J, McManus BM. Apoptosis in cardiac transplant rejection. Cardiology Clinics 2001;19(1);141-54.
  3. Miller LW, Missov ED. Epidemiology of heart failure. [Review] [30 refs]. Cardiology Clinics. November 2001;19(4);547-55.
  4. Rose EA, Geljns AC, Moskowitz AJ, Miller LW, Frazier OH, Desvigne-Nickens P, Oz MC, Poirier VL. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term mechanical left ventricular assistance for end-stage heart failure. New England Journal of Medicine 2001;345(20):1435-43.
  5. Philipp BL, Merewood A, Miller LW, Chawla N, Murphy-Smith MM, Gomes JS, Cimo S, Cook JT. Baby-friendly hospital initiative improves breastfeeding initiation rates in a US hospital setting [see comment]. Pediatrics 2001;108(3);677-81.
  6. Halloran PF, Miller LW, Urmson J, Ramassar V, Zhu LF, Kneteman NM, Solez K, Afrouzian M, IFN-gamma alters the pathology of graft rejection: protection from early necrosis. Journal of Immunology 2001;166(12):7072-81.
  7. Stevenson LW, Kormos RL, Bourge RC, Gelijns A. Griffith BP, Hershberger RE, Hunt

S, Kirklin J, Miller LW, Pae WE Jr., Pantalos G. Pennington DG, Rose EA, Watson JT, Willerson JT, Young JB, Barr ML, Costanzo MR, Desvigne-Nickens P, Feldman AM, Frazier OH, Mechanical Cardiac Support 2000: current applications and future trial design. J Am Coll Cardiology. Jan 2001; 37(1):340-70.

  1. Rose AG, Park SJ, Bank AJ, Miller LW. Aortic valve stenosis induced by left

ventricularassist device (LVAD). J Heart Lung Transplant. Feb 2001; 20(2): 190.

  1. Kirklin J, Miller LW, Brown RN, Alvarez RJ, Porter CB, Vanbakel AB, Jaski BE,

Wannenburg T, White-Williams C, Bourge RC. Who is most likely to enjoy long-term survival after    cardiac transplantation? Risk stratification in a 10-year multi-institutional experience. J Heart Lung Transplant. Feb 2001; 20(2):168-169.

  1. Nguyen DQ, Ormaza S, Miller LW, Bittner HB, Rose AG, Bolman RM, Park SJ. Left

ventricular assist device support for medically unresponsive pulmonary hypertension from left ventricular failure. J Heart Lung Transplant. Feb 2001; 20(2):190.

  1. Miller LW, Granville DJ, Narula J, McManus BM. Apoptosis in cardiac transplant

ejection. Cardiol Clin. Feb 2001; 19(1):141-54.

  1. Wong CK, Ganz P, Miller L, Kobashigawa J. Role of vascular remodeling in the pathogenesis of early transplant   coronary   artery disease: a multicenter prospective intravascular ultrasound study. J Heart Lung Transplant. April 2001; 20:385-392.
  2. Afrouzian M. IFN-gamma alters the pathology of graft rejection: protection from early necrosis. J Immunol. June 2001; 166(12):7072-81
  3. Miller LW, Missov ED. Epidemiology of heart failure. Cardiology Clinics. November

2001; 19:547-555.

  1. Dossari GA, Ormaza S, Savid K, Bolman RM, Miller LW, Park SJ. Left Ventricular

assist device therapy for acute myocardial infarction complicated by cardiogenic shock. J Heart Lung      Transplant. 2002; 21(2):106.

  1. Rose AG, Park SJ, Shumway SJ, Norton D, Miller LW. Acquired supravalvar aortic stenosis following heart transplantation: Report of 2 Cases. J Heart Lung Transplant. April 2002; 21(4): 499-502.
  2. Leier CV, Silver MA, Rich MW, Eichhorn EJ, Fowler MB, Giles TD, Johnstone DE, LeJemtel TH,  Lachmann JS, Baughman KL, Binkley PF, Ventura HO, Francis GS, Miller LW, Nuggets, pearls, and vignettes of master heart failure clinicians. Cong Heart Fail. Mar-Apr 2002; 8(2): 98-124.
  3. Park SJ, Zhang J, Ye Y, Ormaza S, Liang P, Bank AJ, Miller LW, Bache RJ. Myocardial

creatine kinase expression after left ventricular assist device support. J Am Coll Cardiol. June 2002;  39(11): 1773-9.

  1. Bostom AD, Brown RS Jr, Chavers BM, Coffman TM, Cosio FG, Culver K, Curtis JJ, Miller LW, Payne WD, Rosenson R, Sutherland DE, Tejani A, Textor S, Valantine HA, Wiesner RH. Prevention of post-transplant cardiovascular disease – report and recommendations of an ad hoc group. Am J Transplant. July 2002; 2(6):491-500.
  2. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. Oct

2002; 2(9):807-818.

  1. Rose AG, Park SJ, Shumway SJ, Norton D, Miller LW. Acquired supravalvular aortic stenosis following heart transplantation: report of 2 cases. Journal of Heart &Lung Transplantation 2002;21(4):499-502.
  2. Leier CV, Silver MA, Rich MW, Eichhorn EJ, Fowler MB, Giles TD, Johnstone DE, Le Jemtel TH, Lachmann JS, Levine TB, Armstrong PW, Dec WG, Jessup M, Howlett J, Hershberger RE, Cohn JN, Adams KF JR., Colucci WS, Warner-Stevenson L, Hosenpud JD, Bristow MR, Pina E. Nuggets pearls, and vignettes of master heart failure clinicians. Part 4 – treatment. Congestive Heart Failure 2002;8(2):98-124.
  3. Kaufman GE, Cimo S, Miller LW, Blass EF. An evaluation of the effects of sucrose on neonatal pain with 2 commonly used circumcision methods. American Journal of Obstetrics & Gynecology 2002;186(3):564-8.
  4. Park SJ, Zhang J, Ye Y, Ormaza S, Liang P, Bank AJ, Miller LW, Bache RJ. Myocardial creatine kinase expression after left ventricular assist device support. Journal of the American College of Cardiology 2002;39(11):1773-9.
  5. Gray L, Miller LW, Philipp BL, Blass EM. Breastfeeding is analgesic in healthy newborns. Pediatrics 2002;109(4):590-3.
  6. Muehling OM, Wilke NM, Panse P, Jerosch-Herold M, Wilson BV, Wilson RF, Miller LW. Reduced myocardial perfusion reserve and transmural perfusion gradient in heart transplant arteriopathy assessed by magnetic resonance imaging. Journal of he American College of Cardiology 2003;42(6):1054-60.
  7. Chen Y, Park S, Li Y, Missov E, Hou M, Han X, Hall JL, Miller JW, Bache RJ. Alterations of gene expression in failing myocardium following left ventricular assist device support. Physiological Genomics 2003;14(3):251-60.
  8. Miller LW. Patient selection for the use of ventricular assist devices as a bridge to transplantation. Annals of Thoracic Surgery 200375(6 Suppl):S66-71.
  9. Miller LW. Limitations of current medical therapies for the treatment of heart failure. Reviews in Cardiovascular Medicine 2003;4 Suppl 2:S21-9.
  10. Oz MC, Gelijns AC, Miller LW, Nickens P, Aronson R, Aaronson K. Left ventricular assist devices as permanent heart failure therapy: the price of progress.     Annals of surgery 238 (4), 577
  11. Rose AG, Connelly JH, Park SJ, Frazier OH, Miller LW, Ormaza S. Total left ventricular outflow tract obstruction due to left ventricular assist device-induced sub-aortic thrombosis in 2 patients with aortic valve bioprosthesis. Journal of Heart & Lung Transplantation 2003;22(5):594-9.
  12. Liao KK, Miller LW, Toher C, Ormaza S, Herrington CS, Bittner HB, Park SJ. Timing of

transesophageal echocardiography in diagnosing patent foramen ovale in patients supported with left ventricular device. Ann Thorac Surg. May 2003; 75(5):1624-1626.

  1. Huang X, Pan W, Park S, Han X, Miller LW, Hall J. Modeling the relationship between

LVAD support time and gene expression changes in the human heart by penalized partial least squares. Bioinformatics. Apr 2004; 20(6):888-94.

  1. Park SJ, Liao KK, Segurola R, Madhu KP, Miller LW. Management of aortic insufficiency in patients with left ventricular assist devices: a simple coaptation stitch method (Park’s Stitch). Journal of Thoracic & Cardiovascular Surgery. Jan 2004; 127(1):264-6.
  2. Hall JL, Grindle S, Han X, Fermin D, Park S, Chen Y, Bache RJ, Mariash A, Guan Z,

Ormaza S, Thompson J, Graziano J, de Sam Lazaro SE, Pan S, Simari RD, Miller LW. Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks. Physiological Genomics. May 2004; 17(3):283-91.

  1. Huebert RC, Li Q, Miller LW, Hall JL. Identification and regulation of Sprouty 1, a negative inhibitor of the ERK cascade, in the human heart. Physiological Genomics. Aug 2004; 18(3):284-9.
  2. Stevenson LW, Miller LW, Desvigne-Nickens P, Ascheim DD, Parides MK, Renlund DG Mancini D; REMATCH Investigators. Left ventricular assist device as destination for patients undergoing intravenous intropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). Circulation. Aug 2004; 110(8):975-81.
  3. Lietz K, Miller LW. Left ventricular assist devices: evolving devices and indications for

use in ischemic heart disease. Current Opinion in Cardiology. Nov 2004;19(6):613-8.

173 Kittleson MM, Ye SQ, Irizarry RA, Minhas KM, Edness G, Conte JV, Parmigiani G,

Miller LW, Chen Y, Hall JL, Garcia JG, Hare JM. Identification of a gene expression profile that differentiates between ischemic and non-ischemic Cardiomyopathy. Circulation. Nov 2004; 110(22):3444-51.

  1. Lietz K, Miller LW. Current understanding and management of allograft vasculopathy. Seminars in    Thoracic & Cardiovascular Surgery 2004;16(4):386-94.
  2. Birks EJ, Hall JL, Barton P, Grindle S, Miller LW, Yacoub MH. Gene profiling changes in cytoskeletal proteins during clinical recovery following left ventricular assist device (LVAD) support. Circulation Supplement, Vol. 11. No. 7, III-632 (2939), 2004.

176  Miller LW, Lietz K. Cardiac remodeling and recovery: lessons from mechanical

ventricular assist devices. J Ht Lung Transplant 2004. Volume 8(8);33-39.

  1. Miller LW, Sablle J, Goelet P, Sheetz MP, Cornish VW. Methotrexate conjugates : a molecular in vivo      protein tag. Angewandte Chemie. International Ed. In English 2004;43(13):1672-5.
  2. Holman WL, Park SJ, Long JW, Weinberg A, Pagani FD, Miller LW, Naka Y, REMATCH Investigators. Infection in permanent circulatory support: experience from the REMATCH trial. Journal of Heart & Lung Transplantation 2004;23(12):1359-65.
  3.  Park SJ, Liao KK, Segurola R, Madhu KP, Miller LW. Management of aortic insufficiency in patients with left ventricular assist devices: a simple coaptation stitch method (Park’s stitch). Journal of Thoracic & Cardiovascular Surgery 2004;127(1):264-6.
  4. Lietz K, Miller LW. Left ventricular assist devices: evolving devices and indications for use in ischemic heart disease. Current Opinion in Cardiology 2004;19(6):613-8.
  5.  Lietz K, Miller LW. Will left ventricular assist device therapy replace heart

transplantation in the foreseeable future? Current Opinion in Cardiology 2005;20(2):132-7.

  1. Huang X, Pan W, Grindle S, Han X, Chen Y, Park SJ, Miller LW, Hall J. A comparative study of discriminating human heart failure etiology using gene expression profiles. BMC Bioinformatics 2005;6:205.
  2. Birks EJ, Hall JL, Barton PJ, Grindle S, Miller LW, Yacoub MH. Gene profiling changes in cytoskeletal proteins during clinical recovery after left ventricular-assist device support. Circulation 2005;112(9 Suppl):157-64.
  3. Barton PJ, Felkin LE, Birks EJ, Cullen ME, Banner NR, Grindle S, Hall JL, Miller LW, Yacoub MH. Myocardial insulin-like growth factor-I gene expression during recovery from heart failure after combined left ventricular assist device and clenbuterol therapy. Circulation 2005;112:146-50
  4. Rivard AL, Hellmich C, Sampson B, Bianco RW, Crow SJ, Miller LW. Preoperative predictors for postoperative problems in heart transplantation: psychiatric and psychosocial considerations. Progress in Transplantation 2005;15(3):276-82.
  5. Muehling OM, Panse P, Jerosch-Herold M, Wilson BV, Wilson RF, Wilke NM, Miller LW. Cardiac magnetic resonance perfusion imaging identifies transplant arteriopathy by a reduced endomyocardial resting perfusion. Journal of Heart & Lung Transplantation 2005;24(8):122-3.
  6. Binanay C, Califf RM, Hasselblad V, O’Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW. ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005;294(13):1625-33.
  7.  Huang X, Pan W, Han X, Chen Y, Miller LW, Hall J. Borrowing information from relevant microarray studies for sample classification using weighted partial least squares. Computational Biology & Chemistry 2005;29(3):204-212

189     Miller LW, Cai Y, Sheetz MP, Corrish VW. In vivo protein labeling with trimethoprim conjugates: a flexible chemical tag. Nature Methods 2005;2(4):255-7.

190     Miller LW, Corrish VW. Selective chemical labeling of proteins in living cells. Current Opinion in Chemical Biology 2005;9(1):56-61.

191     Kobashigawa JA, Tobis JM, Mentzer RM, Valantine HA, Miller LW, Tanaka K. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. American Journal of Transplantation 2006;6(5 pt 1):993-7.

192     Pagani FD, Long JW, Dembitsky WP, Miller LW. Improved Mechanical Reliability of the HeartMate XVE Left Ventricular Assist System. The Annals of Thoracic Surgery 2006; 82:1413-1418.

  1. Hall JL, Birks EJ, Grindle S, Barton P, Pagani F, Yacoub MH, Miller LW. Molecular signature of recovery following left ventricular assist device (LVAD) support. European Heart Journal, In Press, Feb. 2007.
  2. Drazner MH, Yancy CW, Shah MR, Nohria A, Leier CV, Miller LW, Grancis GS, DiSalvo TG, Califf RM, Stevenson LW. Utility of the history and physical examination in assessing hemodynamics in patients with advanced heart failure: The ESCAPE Trial. Circulation. Submitted May 2005.
  3. Rider JE, Charles NJ, Adhikari N, Polster S, Taylor DA, Miller LW, Hall JL. Mechanistic changes induced

by a selective B2 receptor agonist in a murine model of heart failure. Circ 2005. 112(2):312-318.

  1. Lietz K, Herre JM, Miller LW. The natural history of cardiac allograft systolic function and determinants of functional capacity in the U.S. population of heart transplant recipients. J Heart and Lung Transplantation 2005. 33:212-219
  2. Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR, Eisen HJ, Salm K, Tolzman D, Gao J, Fitzsimmons WE, First MR. A Randomized, Prospective, Multicenter Comparison of Tacrolimus in Combination with Mycophenolate Mofetil or Sirolimus and Steroids vs Cyclosporine Microemulsion in Combination with Mycophenolate Mofetil and Steroids in De Novo Cardiac Transplant Recipients –1 Year Report. Am J Transplantation. 2006;21:445-466.
  3. Rivard A, Swingen C, Blake D, Huang A, Kanth P, Thompsen G, Cordova E, Wilke N, Miller LW,. A Comparison of Myocardial Perfusion and Rejction in Cardiac Transplant Patients. North American Society for Cardiac Imaging. 2005; 12:23-28.
  4. Miller LW, Nelson K, Bostic R, Tong K, Slaughter M, Long, JW. Hospital costs for Left Ventricular Assist Devices for destination therapy: lower costs for implantation in the post-REMATCH era. Journal of Heart and Lung Transplantation. 2007; .
  5.  Drazner MH, Yancy CW, Shah MR, Nohria A, Leier CV, Miller LW, Grancis GS, DiSalvo TG, Califf RM, Stevenson LW. Utility of the history and physical examination in assessing hemodynamics in patients with advanced heart failure: The ESCAPE Trial. Circulation. Submitted May 2005.
  1. Rider JE, Charles NJ, Adhikari N, Polster S, Taylor DA, Miller LW, Hall JL. Mechanistic changes induced by a selective B2 receptor agonist in a murine model of heart failure. Circulation 2007;115:12-3-126
  2. Lietz K, Long J, Kfoury AG, Slaughter MS, Silver MA, Milano CA, Rogers J, and Miller LW. Outcomes of left ventricular assist device implantation in the post REMATCH era: Implications for patient selection.   Circulation 2007;116:497-505.
  3. R John, K Liao, K Lietz, F Kamdar, M Colvin-Adams, A Boyle, L Miller, Experience with the Levitronix CentriMag circulatory support system as a bridge to decision in patients with refractory acute cardiogenic shock and multisystem organ failure. Journal of Thoracic and Cardiovascular Surgery 134 (2), 351-358
  4. Shah MR, Miller LW. Use of pulmonary artery catheters in advanced heart failure. Current Opinion in Cardiology. 2007;22:220-224
  5. Lietz KL, Miller LW. Improved Survival of Patients With End-Stage Heart Failure Listed for Heart TransplantationAnalysis of Organ Procurement and Transplantation Network/US United Network of Organ Sharing Data, 1990 to 2005. J American College of Cardiology 50 (13), 1282-1290
  6.  Kobashigawa J, Miller LW, Mancini D, Bourge R. Prospective, Multicenter Comparison of Tacrolimus in Combination with Mycophenolate Mofetil or Sirolimus and Steroids vs Cyclosporine Microemulsion in Combination with Mycophenolate Mofetil and Steroids in De Novo Cardiac Transplant Recipients –1 Year Report. Am Jof Transplantation 2006: 12;248-261.
  7. John R, Liao K, Lietz K, Colvin-Adams M, Boyle A, Miller L, Joyce L. Experience with Levitronix centrimag circulatory support system as a bridge to decision in patients with refractory acute cardiogenic shock and multisystem organ failure. J of Thoracic and CV Surgery. 2007; 134:351-8.
  8. Maybaum S, Mancini D, Starling R, Aaronson K, Pagani F, Torre-Amione G, Miller LW. Cardiac improvement during mechanical circulatory support: A prospective, multi-center study of the LVAD Working Group. Circulation 2007;115:2497-2505.
  9. Miller LW. Coronary microvasculopathy after heart transplantation: A new marker to guide future trials? Circulation 2007; 116:1224-1225
  10. Miller LW, Nelson K, Bostic R, Tong K, Slaughter M, Long, JW. Hospital costs for Left Ventricular Assist Devices for destination therapy: lower costs for implantation in the post-REMATCH era. Journal of Heart and Lung Transplantation 2007;54:156-66.
  11. Miller, LW, Pagani FP, Boyle A, Russell, SA, Aaronson KD, Conte JV, for the Heartmate II

investigators. New England Journal of Medicine. 2007;357:944-952

  1.  Lietz K, Miller LW. Improved survival of Patients with End-Stage heart failure listed for   heart transplantation. J Am College of Cardiology 2007;50(3):1282-90
  2. Miller LW. Heart failure: who we treat versus who we study. Cardiology Clinics. 2008; 26(1):113-25
  3. Yacoub MH. Miller LW. Long-term left-ventricular-assist-device therapy is here to stay. Nature Clinical Practice Cardiovascular Medicine. 5(2):60-1, 2008 Feb.
  4. O’Connell JB, McCarthy PM, Young JB, Miller LW, Mehra MR, Roland E, Blair JE, Farrar DJ, Gheorghiade M. Mechanical circulatory support devices for acute heart failure syndromes: considerations for clinical trial design. Heart Fail Rev. 2008; 16:233-245.
  5. Russo MJ, MD, Gelijns AC, Stevenson LW, Ascheim DD, Oz MC,, MD, Moskowitz AJ, Rose EA, and Miller LW. The Cost of Medical Management in Advanced Heart Failure During the Final Two Years of Life. J Cardiac Failure; 2008 14(8):651-660
  6. Miller LW. Stem Cell Transplantation: A Call for Standardization. J of Translational CV Research 2008; 4:76-79.
  7. Miller, LW. Continuous aortic flow augmentation: Not enough MOMENTUM. Editorial Circulation. 2008 Sept. 16; 118 (12): 1223-4.
  8. John R, Miller LW. Physiologic and Pathologic Changes in Patients with Continuous Flow   Left Ventricular Assist Devices. J Thor CV Surg. 2008: 118(4):211-218
  9. Lietz K. Miller LW. Patient selection for left-ventricular assist devices. Current Opinion in Cardiology. 24(3):246-51, 2009 May.
  10. Kahwash R, Lier C, Miller LW. Role of the Pulmonary Artery Catheter in Diagnosis and Management of Heart Failure.   Heart Failure Clinics 2009 5(2):241-249
  11. Park SJ, Miller LW, Hall JL. Enhancing Patient Care through Innovation: Open Heart Surgery to Discovery Research. JCVTranslational Research. 2009   3(1):28-35).
  12. Miller LW. Impact of Ventricular Assist Devices on Outcome following heart transplantation: A different view.   JACC 2009; 54(1):445-446
  13. Fermin DR, Barac AF, Hall JL, Miller LW. Heart Failure Sex and Age Dimorphism of Myocardial Gene Expression in Nonischemic Human Heart Failure. Circulation Genetics: 2009: 108.(80):2650-2658
  14. Pagani FP, Miller LW, Russell SF, Boyle A, Frazier OH et al: Longer Term Outcomes with the Heartmate II Continuous Flow Pump in Patients Listed for Heart Transplant. JACC 2009; 54(4): 330-336
  15. Rider, JE. Polster SP. Lee S. Charles NJ. Adhikari N. Mariash A. Tadros G. Stangland J. Smolenski RT. Terracciano CM. Barton PJ. Birks EJ. Yacoub MH. Miller LW. Hall JL. Chronic treatment with clenbuterol modulates endothelial progenitor cells and circulatin factors in a murine model of cardiomyopathy. Journal of Cardiovascular Translational Research . 2(2):182-90, 2009 June
  16. Lietz K. Long JW. Kfoury AG. Slaughter MS. Silver MA. Milano CA. Rogers JG. Miller LW. Deng M. Naka Y. Mancini D. Impact of center volume on outcomes of left ventricular assist device implantation as destination therapy: analysis of the Thoratec HeartMate Registry, 1998 to 2005.Circulation: Heart Failure. 2(1):3-10, 2009 Jan.
  17. Pagani FD. Miller LW. Russell SD. Aaronson KD. John R. Boyle AJ. Naka Y. Mancini D. Moazami N. Ewald GA. Farrar DJ. Frazier OH. HeartMate II Investigators. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. Journal of the American College of Cardiology. 54(4):312-21, 2009 Jul 21.
  1. Miller LW. Outcomes of Medicare beneficiaries with ventricular assist devices.            301(16):1656-7; 1658, 2009 Apr 22.
  2. Levy WC. Mozaffarian D. Linker DT. Farrar DJ. Miller LW. REMATCH Investigators Can the Seattle heart failure model be used to risk-stratify heart failure patients for potential left ventricular assist device therapy? J Heart & Lung Transplantation. 2009. 28(3):231-7.
  3. Russell S, Miller LW, Pagani FD. Advanced Heart Failure: A Call to Action Congestive Heart Failure. 14(6):316-21, 2009 Sept.
  4. Lietz K, Long JW, Slaughter MS, Silver MA, Miller LW, Rogers JG, et al. Impact of Center Volume on Left Ventricular Assist Device Implantation as Destination Therapy: Analysis of the Thoratec Heartmate XVE Registry (1998-2005). Circulation Heart Failure 2009; 2:3-10
  5. Miller LW. Pulsatile Blood Flow: Is it still necessary? Circulation 201(7): 188-193Oct 2009
  6. Miller LW, John R. Complications of Mechanical Circulatory Support in the Continuous Flow Pump Era. Expert Review of Medicine. Invited Manuscript
  7. Slaughter, M, Pagani FG, Aaronson K, Miller LW. Patients with the Heartmate II Continuous Flow Left Ventricular Assist Device: Incidence, Risk Factors, and Impact on Outcomes. Journal of Thoracic & Cardiovascular Surgery. 139(5):1316-24, 2010 May.
  8. Terracciano CM, Miller LW, Yacoub MH. Contemporary Use of Ventricular Assist   . Nature Clinical Medicine. Invited Review. Jan. 2010 15:27-36
  9. Miller LW. Depletion of von Willebrand Factor as a cause of GI bleeding in patients supported with continuous flow LVADs: JACC 2010 55(25): 2460-2462.
  10. Miller LW. The development of the von Willebrand Syndrome with the use of continuous flow left   ventricular assist devices: a cause and effect relationship. Journal of the American College of Cardiology. 56(15):1214-5, 2010 Oct 5.
  11. Kormos RL, Teuteberg JJ, Pagani FD, Russell SD, Miller LW, Milano CA. Moazami N. Farrar DJ.    HeartMate II Clinical Investigators. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. Journal of Thoracic & Cardiovascular Surgery. 139(5):1316-24, 2010
  12. Dib N. Menasche P. Bartunek JJ. Zeiher AM. Terzic A. Chronos NA. Henry TD. Peters NS. Yacoub M. Sanborn TA. Demaria A. Itescu S. Miller LW. Hall JL. Holmes DR J Am Coll of Cardiology: Cardiovascular Interventions. 3(3):265-75, 2010 Mar
  13.  Miller LW. Is pulsatile blood flow no longer essential?. 2009. 120(23):2313-4
  14. Miller LW. LVADs are under utilized. Invited manuscript. Circulation 2012. 123(14):1552-8; 2011 A
  15. Aaronson KD, Slaughter MS, Miller LW, McGee EC, Cotts WB, Acker MA. Use of an intrapericardial, continuous flow, centrifugal pump in patients awaiting heart transplantation. Circulation 111.05841
  16.  Hall JL, Fermin DR, Birks EJ, Slaughter M. Eckman P. Miller LW. Journal of the American College of C   Cardiology. 2011 Feb. 57(6):641-52,.
  17. Aaronson KA, Slaughter MA, Boyce SW, Miller LW, McGee E, et al. Use of Magnetic Levitated Continuous Flow LVAD for Bridge to Transplant Patients Circulation 2012. 124(7): 212-220.
  18. Miller, LW. We always need a pulse, or do we?? Journal of Cardiovascular and Translational Research.   2012. 6(3): 296-301
  19.  Miller, LW, Guglin M. Myocardial Recovery with Left Ventricular Assist Devices. J Ht Lung Transplant.
  20. 23(2): 246-252.
  21. Miller, LW, Guglin M, Rogers JG. Cost of ventricular assist devices: Can we afford the progress. Circulation. 127(6):743-748, February 12, 2013
  22. Acker, Michael A. MD; Pagani, Francis D. MD, PhD; et al. Statement Regarding the Pre and Post Market Assessment of Durable, Implantable Ventricular Assist Devices in the United States. Circulation: Heart Failure. 6(1):e1-e11, January 2013.
  23. Aaronson, Keith D. MD, MS; Slaughter, Mark S. MD; Miller, Leslie W. MD; et al.. Use of an Intrapericardial, Continuous-Flow, Centrifugal Pump in Patients Awaiting Heart Transplantation. Circulation. 125(25):3191-3200, June 26, 2012
  24. Miller, LW, Guglin M, Rogers J. Patient selection for Mechanical Circulatory Support. Journal Am Coll Cardiology. 2013;61:1209-21
  25. Miller LW, Guglin M. LVADs for Destination Therapy. Invited State-of-the-Art Review JACC. March 2015
  26. Miller, LW, Patel A. Stem Cell and Gene Therapy for Cardiovascular Disease. Invited State-of-the-Art review. JACC Heart Failure (in review)
  27. Miller, LW. Patient selection for Advanced Heart Failure Therapy. Global Cardiology Science and Practice. 2015. (in review)
  28. Cheng G, Miller LW, Penn M, Patel A, et al. SDF-1 gene therapy for patients with ischemic heart failure: Results of a Phase II randomized trial.   Submitted European J of Cardiology (in Review)